AUG 19, 2019 9:36 AM PDT

FDA Approves New Treatment for Extensively Drug-Resistant TB

WRITTEN BY: Tiffany Dazet

Last week, the U.S. Food and Drug Administration (FDA) approved a new treatment for a severe form of multi-drug-resistant tuberculosis of the lungs. According to a press release from the FDA, the treatment consists of a six-month regimen of pretomanid tablets combined with bedaquiline and linezolid—referred to as the BPaL regimen. This is one of three tuberculosis treatments to gain FDA approval in the past 40 years. During clinical trials, about 90% of participants using this treatment recovered within six months.

It’s estimated that 1.6 million people die from tuberculosis every year, killing more than any other infectious disease. An article in Nature states that half a million people worldwide are diagnosed with multi-drug-resistant tuberculosis every year. Of those, 8.5% have XDR TB—extensively drug-resistant tuberculosis—which according to RTI, is resistant to four of the main tuberculosis treatments currently in use worldwide. Mel Spigelman, president of the TB Alliance, told Nature “drug-resistant TB is the largest single source of antimicrobial resistance in the world.”

Pretomanid was developed by RTI International as part of the TB Alliance, which is a non-profit product development partnership established in 2000. The team was led by Dr. Doris Rouse, as RTI International scientist. In a statement from RTI, Dr. Rouse said “I’ve been in wards with patients that are so emaciated, they won’t eat anything, they have fevers, they can’t sleep. But with pretomanid, in a regimen that contains two other drugs, bedaquiline and linezolid, we see improvement within a few weeks.”

The development of pretomanid took nearly 20 years. Dr. Rouse commented, “We’ve worked on this new drug for 19 years and it hasn’t always been an easy path. But as I’ve always said, ‘One of the main ingredients for successful drug development is blessed stubbornness.’”

Affordable pricing will be a major hurdle to make the treatment accessible to impoverished patients. According to Sharonann Lynch, the TB advisor for Doctors Without Borders, only 20% of those who needed bedaquiline were able to afford it. Nature states that a six-month supply of bedaquiline and delaminid can cost hundreds to thousands of dollars. The price of the new treatment is currently under negotiations by the TB Alliance.

Sources: FDA, RTI, Nature
 

About the Author
  • Tiffany grew up in Southern California, where she attended San Diego State University. She graduated with a degree in Biology with a marine emphasis, thanks to her love of the ocean and wildlife. With 13 years of science writing under her belt, she now works as a freelance writer in the Pacific Northwest.
You May Also Like
MAR 16, 2020
Cannabis Sciences
MAR 16, 2020
Cannabis Reduces ADHD Med Use in New Study
As the legalization of medical cannabis increases in the U.S. and around the globe, its effects on a variety of conditions and behaviors are under examinat...
MAR 19, 2020
Infographics
MAR 19, 2020
All You Need to Know About Coronavirus (CoVID-19)
A new coronavirus, first identified in China in December 2019, has caused an outbreak of respiratory illness that was recently named CoVID19. CoVID-19 is s...
MAR 23, 2020
Microbiology
MAR 23, 2020
The Loss of a Sense of Smell May be a Major Symptom of COVID-19
The loss of the sense of smell may be a symptom of a COVID-19 infection in people with no other symptoms....
MAR 24, 2020
Cannabis Sciences
MAR 24, 2020
Florida Won't Cap THC for Patients Under 21
Medical marijuana has been legal in Florida since 2016 when more than 70 percent of voters approved the related measure. In March 2020, Republican lawmaker...
MAR 20, 2020
Technology
MAR 20, 2020
Control Release Technology for Medically Favorable Gases
Researchers have recently developed solid material that can control the release of physiologically favorable gases. The study is critical in administering ...
APR 02, 2020
Immunology
APR 02, 2020
Potential New COVID-19 Vaccine is Delivered by Patch
The coronavirus pandemic caused by SARS-CoV-2 is demanding the world's immediate attention....
Loading Comments...